ILMN · Illumina, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on ILMN. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About ILMN · Illumina, Inc.
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Live Quote
HOLD (score +4) · 12-1 mom 58.2% · RSI 59.5 · above_both · -3.5% from high
Targets blend Wall Street consensus (18 analysts: low $95.00 / mean $149.83 / high $185.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Illumina is a dominant DNA sequencing platform company (92% of revenue from sequencing) that has had an extraordinary run — +77% YTD, near 52-week highs. The stock appears fully-valued at forward P/E ~28x and EV/EBITDA ~23x with modest 4.8% revenue growth. JPMorgan's recent upgrade to Overweight ($185 target vs $165 spot) is a bullish catalyst but represents only ~12% upside — insufficient for an asymmetric long setup, especially given null options chain data making any earnings-based spread strategy unreliable. The board addition of Eli Lilly's R&D Chief (Dr. Skovronsky) on June 16 is the most interesting edge: his drug-discovery and translational medicine expertise signals Illumina's deepening push into clinical genomics and multiomics markets. No material insider open-market purchases were found; one senior officer sale was observed. Given premium valuation, weak options infrastructure, and lack of a mispriced catalyst, this name fits 'range_bound_or_income' if IV were elevated — but with null bid/ask data across all strikes (fatal structure flaw), even income strategies are unsupported. Verdict: no_anomaly.
{"symbol":"ILMN","company":"Illumina, Inc.","investigation_summary":"Illumina has had an extraordinary run (up ~99% over one year, +69% YTD) driven by NovaSeq X adoption acceleration, clinical sequencing demand growth, and consistent earnings beats. The Form 4 trigger was a cluster of filings — but upon reading them closely, they reveal the opposite of bullish insider conviction: Keith Meister's C
Heavy insider distribution ($110M sold vs $300K bought) and active anti-signals (customer concentration, dilution risk) outweigh the earnings catalyst and technical momentum. With the stock up 56% YTD at an elevated forward P/E, neither long nor income structures offer a favorable risk/reward profile.
The Form 4 cluster triggering this investigation is primarily driven by Keith Meister (Corvex Management) converting equity swaps into actual shares and aggressively selling them at current elevated prices — over 700,000 shares sold May-June 2026 in the $140-165 range. This is a DISTRIBUTION pattern from an activist/large holder, not a bullish accumulation signal. Separately, a SVP (Patricia Leckman) made small sales near all-time highs. Meanwhile, fundamentals are strong — Q1 2026 EPS beat by 9%, multiple oncology product launches in May-June 2026 (StrataMap Spatial Solution, fireflyGO automation platform with SPT Labtech, whole-genome WGS MRD research kit, IDT DRAGEN integration), and NovaSeq X adoption accelerating. The stock has run +56% YTD and sits within ~5% of its 52-week high ($160 vs $177). Forward P/E of 27x is elevated versus sector peers, but ILMN's dominance in sequencing justifies a premium. Earnings on July 30 could be a near-term catalyst or inflection point.
Massive insider distribution ($115M sold vs $2.5M bought), rich valuation at/near peak multiples, and overbought technicals (RSI 74.9) make this an unfavorable entry. The bull case is already priced in with no mispricing or asymmetric structure available.
Illumina is a dominant sequencing and array-based genomics platform company ($25B market cap) that has surged ~84% YTD to within 5% of its all-time high. Q1 FY2026 results beat on both EPS (+9% surprise at $1.15 vs $1.055 est.) and revenue, driven by NovaSeq X adoption acceleration, clinical sequencing demand, and early SomaLogic proteomics contribution following the January 2026 acquisition for ~$460M cash + contingent consideration. The stock is richly valued (forward P/E 28.4x, EV/EBITDA 23x) with elevated RSI at 74.9 into a July 30 earnings report that historically beats by 9-18%. Keith Meister's Corvex Capital remains a large shareholder but has been aggressively distributing shares into this rally. The stock lacks the mispricing element — it is fully valued at/near peak multiples, making any new long entry asymmetric-risk-unfavorable. However, with IV elevated from recent volatility and the stock range-bound near 52w high, income strategies (CC/strangle) are structurally viable.
{"symbol":"ILMN","company":"Illumina, Inc.","investigation_summary":"Illumina is a dominant sequencing platform company with strong NovaSeq X momentum and recently raised FY2026 guidance after a Q1 earnings beat. However, the stock has run ~54% YTD to fresh 52-week highs at RSI 76, leaving it fully valued on forward P/E (~26.8x) vs a sector where 20-24x is more typical for compounder names without
Illumina is a fundamentally strong sequencing platform company (FY2025 revenue $4.39B, ~68% gross margins) that has recovered sharply (+52% YTD from September lows) following Q1 2026 earnings beats and raised guidance with an expanded buyback. The Form 4 cluster triggering this investigation was Keith Meister / Corvex converting equity swaps into actual shares then aggressively SELLING those shares at $144-$148 in May 2026 — not a bullish accumulation signal, but rather a distribution pattern from a large stakeholder who holds ~3.5M remaining shares. The stock is near its 52-week high with elevated RSI (63) and no meaningful pullback in over two months of grinding higher.